Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study
Authors:
- Rikke SørensenRSRikke Sørensen
- Steen Z AbildstromSASteen Z Abildstrom
- Peter WeekePWPeter Weeke
- Emil L FosbølEFEmil L Fosbøl
- Fredrik FolkeFFFredrik Folke
- Morten L HansenMHMorten L Hansen
- Peter R HansenPHPeter R Hansen
- Jan K MadsenJMJan K Madsen
- Ulrik AbildgaardUAUlrik Abildgaard
- Lars KøberLKLars Køber
- Henrik E PoulsenHPHenrik E Poulsen
- Christian Torp-PedersenCTChristian Torp-Pedersen
Open Access
- 29 January 2010
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 10 (1) , 6
Abstract
The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI. Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens. The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p = 0.06). We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.Keywords
This publication has 24 references indexed in Scilit:
- Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide studyBritish Journal of Clinical Pharmacology, 2008
- Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary SyndromeJAMA, 2008
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionCirculation, 2007
- Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of CardiologyEuropean Heart Journal, 2007
- Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-UpThe American Journal of Cardiology, 2006
- Guidelines for Percutaneous Coronary InterventionsEuropean Heart Journal, 2005
- Early and Late Effects of Clopidogrel in Patients With Acute Coronary SyndromesCirculation, 2003
- Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary InterventionJAMA, 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 2001